Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic ...

Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was ...

Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted ...

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement o ...

San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by ...

Since its founding in 2020, Neomorph has inked nearly $5 billion worth of deals with pharmaceutical companies.

Dr. Georg Winter explores how chemical neomorphs can give proteins new functions by reshaping their cellular interactions, ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...

Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...

Over four decades, the Alien franchise has brought many different versions of the xenomorph creature to theaters.

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...